Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 5/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20254831 | 1.00 | CASP2 (0.53) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL23849342 | 1.00 | CASP2 (0.53) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL24155207 | 0.97 | CASP2 (0.56) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL16221915 | 0.97 | CASP2 (0.56) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL24483387 | 0.97 | CASP2 (0.56) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL15759326 | 0.97 | CASP2 (0.56) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL20255020 | 0.96 | CASP2 (0.54) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL16217752 | 0.96 | CASP2 (0.53) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL25962907 | 0.96 | CASP2 (0.53) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL8210240 | 0.88 | CASP2 (0.59) | CASP2FAAHNAAANOD1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| WO-2021186166-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021186169-A1 | ORAL GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | GLP1R, GIPR, NPY4R | CASP2 1462/4885FAAH 621/4885NAAA 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.